Cargando…

Association of immune checkpoint inhibitors therapy with arterial thromboembolic events in cancer patients: A retrospective cohort study

BACKGROUND: Immune checkpoint inhibitors (ICIs) have emerged as a standard treatment for various malignancies. However, research indicates blocking the immune checkpoint pathway may exacerbate atherosclerotic lesions. OBJECTIVES: We aimed to investigate whether ICI therapy increases the risk of arte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Jie, Chen, Yue, Zhang, Yuanlong, Wang, Wei, Wang, Yujue, Lu, Zhuo, Zhang, Yulin, Lei, Haike, Li, Dairong, Long, Bo, Liu, Haixia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557854/ https://www.ncbi.nlm.nih.gov/pubmed/37584246 http://dx.doi.org/10.1002/cam4.6455

Ejemplares similares

Characteristics and Predictors of Venous Thromboembolism Among Lymphoma Patients Undergoing Chemotherapy: A Cohort Study in China
por: Chen, Yue, et al.
Publicado: (2022)

Thromboembolic Events Related to Treatment with Checkpoint Inhibitors: Report of Two Cases
por: Tsukamoto, Jessica, et al.
Publicado: (2018)

Development and Validation of a Risk Prediction Model for Venous Thromboembolism in Lung Cancer Patients Using Machine Learning
por: Lei, Haike, et al.
Publicado: (2022)

Management of immune checkpoint inhibitor‐related rheumatic adverse events
por: Zhou, Jiaxin, et al.
Publicado: (2019)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
por: Si, Xiaoyan, et al.
Publicado: (2019)

Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis
por: Zhang, Yue, et al.
Publicado: (2022)

Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors
por: Zou, Xue-lin, et al.
Publicado: (2021)

Nomogram prediction for the risk of venous thromboembolism in patients with lung cancer
por: Lei, Haike, et al.
Publicado: (2023)

Immune checkpoint inhibitors and potential risk of thromboembolic events: Analysis of the WHO global database of individual case safety reports
por: Alghamdi, Eman A., et al.
Publicado: (2022)

Analysis on the risk of myasthenia gravis related to immune checkpoint inhibitors based on the US FDA Adverse Event Reporting System
por: Kong, Qingli, et al.
Publicado: (2023)

Risk of venous and arterial thromboembolic events associated with tyrosine kinase inhibitors in advanced thyroid cancer: a meta-analysis and systematic review
por: Bai, Yang, et al.
Publicado: (2018)

A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors
por: Lal, Jessica Castrillon, et al.
Publicado: (2021)

Differential Presentations of Arterial Thromboembolic Events Between Venous Thromboembolism and Atrial Fibrillation Patients
por: Lin, Yu-Sheng, et al.
Publicado: (2021)

The risk of arterial thromboembolic events after cancer diagnosis
por: Navi, Babak B., et al.
Publicado: (2019)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated adverse events in the digestive system
por: Li, Yue, et al.
Publicado: (2020)

Management of immune checkpoint inhibitor‐related adverse events: A review of case reports
por: Si, Xiaoyan, et al.
Publicado: (2020)

Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients
por: Nichetti, Federico, et al.
Publicado: (2019)

Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor‐associated adverse events
por: Song, Peng, et al.
Publicado: (2020)

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events
por: Zhuang, Junling, et al.
Publicado: (2020)

Ocular adverse events with immune checkpoint inhibitors
por: Fang, Tony, et al.
Publicado: (2019)

Mucocutaneous adverse events to immune checkpoint inhibitors
por: Muhaj, Fiorinda, et al.
Publicado: (2023)

Unexpected Adverse Events of Immune Checkpoint Inhibitors
por: Shalata, Walid, et al.
Publicado: (2023)

Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
por: Xiao, Yan, et al.
Publicado: (2020)

Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors
por: Wang, Zheng-Hang, et al.
Publicado: (2018)

Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors
por: Gan, Linyang, et al.
Publicado: (2023)

Imaging of Adverse Events Related to Checkpoint Inhibitor Therapy
por: Vani, Vanina, et al.
Publicado: (2020)

Cardiac Adverse Events Related to Immune Checkpoint Inhibitors
por: Gujral, Dorothy M., et al.
Publicado: (2020)

Cardiovascular events after the initiation of immune checkpoint inhibitors
por: Suzuki, Yuta, et al.
Publicado: (2023)

Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival
por: Sussman, Tamara A, et al.
Publicado: (2021)

Risk factors for cardiovascular adverse events from immune checkpoint inhibitors
por: Luo, Lingli, et al.
Publicado: (2023)

Efficacy and Safety of Immune Checkpoint Inhibitor in Advanced Esophageal Squamous Cell Carcinoma: A Meta-Analysis
por: Gu, Yi-Min, et al.
Publicado: (2021)

Arterial Thromboembolism
Publicado: (2021)

Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer
por: Liu, Wei, et al.
Publicado: (2020)

Risk analysis for patients with arterial thromboembolic events after intravitreal ranibizumab or aflibercept injections
por: Chou, Yun-I., et al.
Publicado: (2023)

Retrospective Evaluation of Intravenous Enoxaparin Administration in Feline Arterial Thromboembolism
por: Mitropoulou, Athanasia, et al.
Publicado: (2022)

Changes of IL-6 And IFN-γ before and after the adverse events related to immune checkpoint inhibitors: A retrospective study
por: Zhang, Xu, et al.
Publicado: (2022)

Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis
por: Gao, Wen, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors and Neurotoxicity
por: Zhao, Zhiyi, et al.
Publicado: (2021)

Machine learning predicts cancer-associated venous thromboembolism using clinically available variables in gastric cancer patients
por: Xu, Qianjie, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
por: Herrmann, Sandra M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hl8qsemoeqsev5t5lnvghilm9b